Skip header and navigation

Refine By

9 records – page 1 of 1.

Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains.

https://arctichealth.org/en/permalink/ahliterature88983
Source
FEMS Immunol Med Microbiol. 2009 Jul;56(2):116-28
Publication Type
Article
Date
Jul-2009
Author
Hayashi Daisuke
Takii Takemasa
Fujiwara Nagatoshi
Fujita Yukiko
Yano Ikuya
Yamamoto Saburo
Kondo Maki
Yasuda Emi
Inagaki Emi
Kanai Keita
Fujiwara Akiko
Kawarazaki Aya
Chiba Taku
Onozaki Kikuo
Author Affiliation
Department of Molecular Health Sciences, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Source
FEMS Immunol Med Microbiol. 2009 Jul;56(2):116-28
Date
Jul-2009
Language
English
Publication Type
Article
Keywords
Animals
Cell Line
Cells, Cultured
Cord Factors - immunology - isolation & purification
Epithelial Cells - immunology - microbiology
Female
Humans
Interferon-gamma - immunology
Interleukins - secretion
Mice
Monocytes - immunology - microbiology
Mycobacterium bovis - immunology
Nitric Oxide - biosynthesis
Tumor Necrosis Factor-alpha - secretion
Abstract
During the serial passage of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in different countries after initial seed distribution from the Pasteur Institute, specific insertions and deletions in the genome among BCG substrains were observed and speculated to result in differences in immunological activities. 'Early-shared strains' of BCG (Russia, Moreau, Japan, Sweden, Birkhaug), distributed by the Pasteur Institute, which conserve three types of mycolate (alpha, methoxy, keto) in cell wall, exhibited stronger activities of induction of nitric oxide, interleukin-1beta (IL-1beta), IL-6, IL-8, IL-12 and tumor necrosis factor (TNF)-alpha, from human epithelial cell line A549, human myelomonocytic cell line THP-1 and mouse bone marrow cells in the presence of interferon-gamma (IFN-gamma) than did 'late-shared strains' of BCG (Danish, Glaxo, Mexico, Tice, Connaught, Montreal, Phipps, Australia, Pasteur). The stronger induction of IL-12 and TNF-alpha in the presence of IFN-gamma was also observed by trehalose 6,6'-dimycolate (TDM) extracted from BCG-Japan than by TDM from BCG-Connaught, which lacks the methoxymycolate residue. These results suggest that 'early-shared strains' are more potent immunostimulating agents than 'late-shared strains', which could be attributed partially to methoxymycolate. Our study provides the basic information for immunological characterization of various BCG strains and may contribute to a re-evaluation of them as a reference strain for vaccination against tuberculosis.
PubMed ID
19453755 View in PubMed
Less detail

Detection of abacavir hypersensitivity by ELISpot method.

https://arctichealth.org/en/permalink/ahliterature126937
Source
Inflamm Allergy Drug Targets. 2012 Jun;11(3):227-34
Publication Type
Article
Date
Jun-2012
Author
Stefan Esser
Robert Jablonka
Falko M Heinemann
Stefan Reuter
Hans Jaeger
Ariane von Krosigk
Pia Schenk-Westkamp
Dirk Schadendorf
Peter A Horn
Monika Lindemann
Author Affiliation
HIV/STD-Out Patient Clinic, Department of Dermatology and Venerology, University Hospital Essen, Essen, Germany.
Source
Inflamm Allergy Drug Targets. 2012 Jun;11(3):227-34
Date
Jun-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Anti-HIV Agents - adverse effects - therapeutic use
Canada
Dideoxynucleosides - adverse effects - therapeutic use
Drug Hypersensitivity - diagnosis - etiology
Enzyme-Linked Immunospot Assay - methods
Female
HIV Infections - drug therapy
HLA-B Antigens - genetics
Humans
Interferon-gamma - immunology
Leukocytes, Mononuclear - immunology
Male
Middle Aged
Young Adult
Abstract
The antiretroviral agent abacavir can cause hypersensitivity reaction (HSR) and the presence of HLA-B*57:01 is predictive of abacavir-HSR in Caucasian HIV-infected patients. However, abacavir-HSR also occurs in HLA-B*57:01 negative patients. In these patients, a safe diagnostic tool to dissect clinically suspected HSR against abacavir from adverse reactions against co-administered drugs is mandatory, and abacavir-ELISpot was evaluated. Peripheral blood mononuclear cells from 87 HIV patients were stimulated by abacavir and the production of interferon-? to the ELISpot was determined. Abacavir treated patients with HSR [confirmed (n=5) or suspected (n=12)] vs without HSR (n=42) displayed significantly higher numbers of abacavir-specific cells (82.3?23.0 or 10.5?4.5 vs -0.5?1.0 spot forming cells per million PBMC, p
PubMed ID
22338581 View in PubMed
Less detail

[Development of vaccine preparation for urogenital Chlamydiosis prophylaxis].

https://arctichealth.org/en/permalink/ahliterature127290
Source
Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec;(6):114-23
Publication Type
Article
Author
E A Koroleva
N A Zigangirova
Source
Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec;(6):114-23
Language
Russian
Publication Type
Article
Keywords
Adjuvants, Immunologic - chemical synthesis
Animals
Antigens, Bacterial - immunology
Bacterial Vaccines - chemistry - immunology
CD4-Positive T-Lymphocytes - immunology - secretion
Chlamydia Infections - epidemiology - immunology - microbiology - prevention & control
Chlamydia trachomatis - immunology - pathogenicity
Chronic Disease
Female
Genitalia, Female - microbiology
Genitalia, Male - microbiology
Humans
Immunity, Cellular
Interferon-gamma - immunology
Male
Mice
Russia
Vaccines, DNA - chemistry - immunology
Vaccines, Subunit - chemistry - immunology
Abstract
Chlamydia trachomatis is one of the most widespread bacterial pathogens in the world that is transmitted sexually. Thereby a development of vaccine preparation for therapy and prophylaxis of infections caused by C. trachomatis is an actual topic of scientific research across the entire world. These vaccines could be used for both prophylaxis and therapy of already established chlamydia infection and, respectively, reduce the risk of chronic condition and prevent the spread of pathogen in the population. Features of chlamydia biology that are associated with obligate intracellular parasitism and immunopathologic state induced by this agent significantly complicate developments in this field. Currently a vaccine preparation that has reached clinical trials does not exist.
PubMed ID
22308743 View in PubMed
Less detail

[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].

https://arctichealth.org/en/permalink/ahliterature116892
Source
Antibiot Khimioter. 2012;57(7-8):23-30
Publication Type
Article
Date
2012
Author
A V Aver'ianov
A P Babkin
B Ia Bart
A L Volchetskii
E S Minina
O A Kozyrev
M P Kostinov
D V Petrov
E P Sel'kova
M A Putilovskii
V B Nechaev
O I Epshtein
E N Andrianova
Source
Antibiot Khimioter. 2012;57(7-8):23-30
Date
2012
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Antigens, CD4 - immunology
Antipyretics - therapeutic use
Antiviral agents - therapeutic use
Body temperature
Female
Fever - drug therapy
Histamine - immunology
Humans
Influenza, Human - drug therapy - etiology
Interferon-gamma - immunology
Male
Middle Aged
Oseltamivir - therapeutic use
Russia
Time Factors
Treatment Outcome
Young Adult
Abstract
The narrow range of choice and virus resistance to the most common drugs require search and introduction of new drugs with proven efficacy and safety for the treatment of influenza. Ergoferon is a new combined medicine containing release active antibodies to interferon-gamma (anti-IFNgamma), CD4-coreceptor and histamine. The formulation influences various links of antiviral defense and provides antiinflammatory effect. The efficacy of the drug is related to its production process during which multiple reduction of the initial concentration of every component leads to release of special release activity. Previous experimental studies showed that anti-IFNgamma had antiviral activity against pandemic influenza virus A (H1N1) 2009 comparable to that ofoseltamivir (suppression of virus replication in the lung tissue, increase of the lifespan and reduction of the laboratory animals mortality). The aim of the multicentre randomized clinical trial was to compare (versus oseltamivir) the efficacy and safety of ergoferon in the treatment of influenza in adults. 213 patients with flu-like symptoms were examined in 8 medical centres of Russia during two epidemiological seasons (2010-11 and 2011-12). The inclusion criteria were: the first 48 hours after the onset; fever > or =37.8 degrees C, at least one common symptom and at least one respiratory symptom. Influenza was confirmed in 52 patients by QuickVue rapid diagnosis. 23 patients received ergoferon according to the treatment scheme and 29 received oseltamivir (daily dose 150 mg). Duration of the treatment was 5 days. The patients were followed up for 7 days. The primary endpoint was the percentage of the patients with the body temperature normalization for 2-5 days of the treatment. The maximum efficacy of ergoferon was observed on the second day of the treatment: almost half (48%) of the initially febrile patients had normal body temperature (versus 28% in the patients treated with oseltamivir). The comparison of the two groups of the patients by the morning and evening measurements of the body temperature every five days of the treatment by Cochran-Mantel-Haenszel revealed a significant difference between the two groups (chi2 = 7.1; p = 0.008). The average duration of the fever in the group of ergoferon was 2.3 +/- 1.2 days, in the group of oseltamivir--2.6 +/- 1.3 days (the efficacy of oseltamivir in the present study was comparable with the previously published data). The percentage of the patients treated with antipyretics because of hyperthermia on the second day of the treatment lowered 3 times and amounted to 17% (versus 41% in the oseltamivir group). The severity of common and respiratory symptoms (nose/throat/chest) significantly decreased on the third day of the treatment in both groups, the majority of the patients had either minimum severity or no signs of influenza. The clinical improvement was associated with positive changes in the life quality. No cases of the disease aggravation were recorded. Complications requiring antibiotic treatment or hospitalization were not observed during the followup. There were no adverse events recorded due to the drug use. No deviations in the laboratory indices were stated. Ergoferon is a new safe drug for the treatment of influenza. Its clinical efficacy was comparable to that of oseltamivir. The therapeutic effects of the drug were evident from: significant reduction of the disease severity, duration of febricity and general toxicity and respiratory flu symptoms, lower percentage of the patients with fever for 2 days. The febrile period in most of the patients did not exceed 2 days.
PubMed ID
23350191 View in PubMed
Less detail

HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

https://arctichealth.org/en/permalink/ahliterature108526
Source
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13492-7
Publication Type
Article
Date
Aug-13-2013
Author
Tomer Hertz
Christine M Oshansky
Philippa L Roddam
John P DeVincenzo
Miguela A Caniza
Nebojsa Jojic
Simon Mallal
Elizabeth Phillips
Ian James
M Elizabeth Halloran
Paul G Thomas
Lawrence Corey
Author Affiliation
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. thertz@fhcrc.org
Source
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13492-7
Date
Aug-13-2013
Language
English
Publication Type
Article
Keywords
CD4-Positive T-Lymphocytes - immunology
Cohort Studies
Computational Biology - methods
Enzyme-Linked Immunospot Assay
Gene Frequency
HLA Antigens - immunology - metabolism
Humans
Influenza A Virus, H1N1 Subtype
Influenza, Human - epidemiology - immunology
Interferon-gamma - immunology
Models, Statistical
Regression Analysis
Abstract
Experimental and computational evidence suggests that HLAs preferentially bind conserved regions of viral proteins, a concept we term "targeting efficiency," and that this preference may provide improved clearance of infection in several viral systems. To test this hypothesis, T-cell responses to A/H1N1 (2009) were measured from peripheral blood mononuclear cells obtained from a household cohort study performed during the 2009-2010 influenza season. We found that HLA targeting efficiency scores significantly correlated with IFN-? enzyme-linked immunosorbent spot responses (P = 0.042, multiple regression). A further population-based analysis found that the carriage frequencies of the alleles with the lowest targeting efficiencies, A*24, were associated with pH1N1 mortality (r = 0.37, P = 0.031) and are common in certain indigenous populations in which increased pH1N1 morbidity has been reported. HLA efficiency scores and HLA use are associated with CD8 T-cell magnitude in humans after influenza infection. The computational tools used in this study may be useful predictors of potential morbidity and identify immunologic differences of new variant influenza strains more accurately than evolutionary sequence comparisons. Population-based studies of the relative frequency of these alleles in severe vs. mild influenza cases might advance clinical practices for severe H1N1 infections among genetically susceptible populations.
Notes
Cites: N Engl J Med. 2009 Nov 12;361(20):1925-3419815860
Cites: Biochem Biophys Res Commun. 2009 Dec 18;390(3):349-5119769939
Cites: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-7019918065
Cites: Euro Surveill. 2009;14(42). pii: 1936619883543
Cites: MMWR Morb Mortal Wkly Rep. 2009 Aug 28;58(33):913-819713879
Cites: MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-419478718
Cites: J Med Genet. 2009 Jul;46(7):469-7119429597
Cites: J Virol. 2009 Sep;83(18):9206-1419553306
Cites: J Virol. 2009 Jun;83(11):5485-9419297491
Cites: MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1341-420010508
Cites: PLoS One. 2010;5(1):e875420090904
Cites: CMAJ. 2010 Feb 23;182(3):257-6420093297
Cites: Science. 2010 Apr 16;328(5976):357-6020339031
Cites: Southeast Asian J Trop Med Public Health. 2010 May;41(3):562-920578543
Cites: Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12599-60420616031
Cites: J Infect Dis. 2010 Sep 1;202(5):681-920670171
Cites: PLoS Pathog. 2010;6(9):e100111720886101
Cites: Protein Cell. 2010 May;1(5):459-6721203961
Cites: J Virol. 2011 Feb;85(3):1310-2121084470
Cites: Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S13-2621342884
Cites: Microbes Infect. 2011 May;13(5):489-50121295153
Cites: Hum Vaccin. 2011 Apr;7(4):402-921471731
Cites: Emerg Infect Dis. 2012 May;18(5):834-722516540
Cites: Pediatr Infect Dis J. 2012 Jun;31(6):e86-9122466328
Cites: Lancet Infect Dis. 2012 Sep;12(9):687-9522738893
Cites: J Forensic Sci. 2012 Nov;57(6):1512-822571830
Cites: Vaccine. 2012 Dec 17;31(1):219-2523099328
Cites: Emerg Infect Dis. 2013 Jan;19(1):92-10123260059
Cites: BMC Public Health. 2012;12:86923061747
Cites: J Clin Invest. 1999 Dec;104(12):R63-710606632
Cites: Science. 2002 May 24;296(5572):1439-4312029127
Cites: J Virol. 2002 Dec;76(23):12388-9312414983
Cites: J Pak Med Assoc. 2002 Jun;52(6):253-612503591
Cites: Annu Rev Med. 2003;54:535-5112525683
Cites: Tissue Antigens. 2003 May;61(5):403-712753660
Cites: Int J Lepr Other Mycobact Dis. 1977 Jul-Sep;45(3):273-7562857
Cites: Nature. 1978 May 18;273(5659):238-9306072
Cites: Cell Immunol. 1979 Mar 15;43(2):341-51113108
Cites: N Engl J Med. 1983 Jul 7;309(1):13-76602294
Cites: Hum Immunol. 1998 Apr;59(4):243-99568800
Cites: J Immunol. 1999 Nov 1;163(9):4673-8210528164
Cites: Am J Hyg. 1958 Sep;68(2):169-8913571231
Cites: Nature. 2005 Oct 20;437(7062):1162-616208317
Cites: FEMS Immunol Med Microbiol. 2006 Jul;47(2):155-6616831202
Cites: Mol Immunol. 2007 Feb;44(6):1253-6116930710
Cites: Nat Med. 2007 Jan;13(1):46-5317173051
Cites: Science. 2007 Mar 16;315(5818):1583-617363674
Cites: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16233-817911249
Cites: BMC Immunol. 2008;9:118211710
Cites: J Clin Invest. 2008 Oct;118(10):3478-9018802496
Cites: J Virol. 2009 Mar;83(6):2743-5519116253
Cites: Nat Med. 2009 Mar;15(3):277-8419234462
Cites: J Virol. 2009 Apr;83(7):3407-1219153230
PubMed ID
23878211 View in PubMed
Less detail

Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.

https://arctichealth.org/en/permalink/ahliterature281782
Source
Transpl Infect Dis. 2015 Jun;17(3):371-9
Publication Type
Article
Date
Jun-2015
Author
A. Ambati
S. Einarsdottir
I. Magalhaes
T. Poiret
R. Bodenstein
K. LeBlanc
M. Brune
M. Maeurer
P. Ljungman
Source
Transpl Infect Dis. 2015 Jun;17(3):371-9
Date
Jun-2015
Language
English
Publication Type
Article
Keywords
Adjuvants, Pharmaceutic
Adult
Aged
CD8-Positive T-Lymphocytes - immunology
Cohort Studies
Female
Humans
Influenza A Virus, H1N1 Subtype - immunology
Influenza A Virus, H3N2 Subtype - immunology
Influenza Vaccines - administration & dosage - immunology
Influenza, Human - immunology - prevention & control - virology
Interferon-gamma - immunology
Male
Middle Aged
Seasons
Stem Cell Transplantation - adverse effects
Sweden
Transplantation, Homologous - adverse effects
Vaccination
Young Adult
Abstract
Influenza vaccination is generally recommended to hematopoietic stem cell transplant (HSCT) recipients. However, the seasonal subunit vaccination response is frequently suboptimal, and alternate more efficient vaccination systems must be examined. We compared the immunogenicity of an adjuvanted virosomal influenza and subunit vaccine in HSCT recipients.
The immunogenicity after a single dose (0.5 mL) of adjuvanted trivalent virosomal vaccination was evaluated in a study cohort of 21 HSCT recipients and compared to a control cohort of 30 HSCT recipients who received a single dose (0.5 mL) of non-adjuvanted seasonal trivalent subunit vaccination over 4 seasons from 2010 to 2014. Whole blood interferon-gamma (IFN-?) release assays were tested, both before and 30 days after vaccination, in response to influenza pandemic (pdm) H1N1, H3N2, and B antigens. HLA-A*02 dextramers, to gauge for the absolute number of antigen-specific CD8(+) T-cells, and pdm 2009 hemagglutinin inhibition (HI) assays, to test for neutralizing antibodies, were used as immunological readouts.
The pdm HI titers were poor in both cohorts with only 23% (5/21) after virosomal vaccination and 13.3% (4/30) in the seasonal vaccine cohort having protective titers (=40). The delta change of IFN-? production in response to influenza pdm H1N1 (P = 0.005) and influenza B antigens (P = 0.01) were significantly elevated in blood from individuals who received the virosomal as compared to the seasonal vaccine. The IFN-? response to pdm H1N1 was stronger (P 6 month post HSCT. We detected a significant increase in the frequency of matrix 1 (GILGFVTL) dextramer-specific CD8(+) T-cells after the virosomal vaccine (P = 0.01). No differences were seen in the hemagglutinin-specific CD8(+) T-cells between the 2 cohorts.
Vaccination using a virosomal delivery system is beneficial in eliciting robust cellular immune responses to pdm H1N1 influenza in SCT recipients.
PubMed ID
25817044 View in PubMed
Less detail

[Local tissue hypoxia consequence in the trophic venous ulceration in elderly patients]

https://arctichealth.org/en/permalink/ahliterature93921
Source
Angiol Sosud Khir. 2007;13(2):79-83
Publication Type
Article
Date
2007
Author
Losev R Z
Zakharova N B
Burov Iu A
Iakusheva E A
Nikitina V V
Stepanova T V
Mikul'skaia E G
Source
Angiol Sosud Khir. 2007;13(2):79-83
Date
2007
Language
Russian
Publication Type
Article
Keywords
Aged
Anoxia - epidemiology - physiopathology
Female
Humans
Interferon-gamma - immunology
Interleukin-4 - immunology
Lower Extremity - blood supply - physiopathology
Male
Retrospective Studies
Tumor Necrosis Factor-alpha - immunology
Varicose Ulcer - epidemiology - immunology - physiopathology
Abstract
This paper analyzes the data of examination and the results of the treatment of 25 patients aged over 80 years (mean age 68.5+/-7 years) suffering from varicosity with long nonhealing trophic ulcers of the distal limb segments (CVI CMP C6) and 20 patients of the same age groups with CVI CEAP stages 3-5. All patients with CVI underwent either full-scope phlebectomy (64.4%) or partial truncal phlebectomy (35.6%), in which the trunk of the greater saphenous vein was stripped up to the upper third of the leg. A TCM-3 outfit (RADIOmeter, Denmark) was employed to measure oxygen tension in limb tissues. Parameters of lipid peroxidation and antioxidant tissue defence were measured intraoperatively in the capillary blood of the fingers as well as in the venous blood withdrawn from the cubital vein and the greater saphenous vein in the lower third of the leg near ulcer). The data obtained evidenced that lipid peroxidation activity was most pronounced in the soft tissues of the lower third of the leg in the group of patients with remarkable chronic venous insufficiency without trophic venous ulcers (GVI CEAP C3-5) and was significantly depleted after formation of varicose ulcers (CVI CEAP C6) associated with remarkable tissue hypoxia (TepO2 1.7-7.0 mm Hg). In all patients with CVI, the syndrome of lipid peroxidation was associated with the lowering of antioxidant defence activity. Patients with trophic venous ulcers had the signs of active inflammation in the soft tissues of the leg. The data obtained in the course of the study made it possible to optimize the treatment policy for elderly patients with trophic venous ulcers. In addition to the lowering of venous hypertension, the treatment included correction of microcirculatory disorders related to local hypoxia. Of special importance was reperfusion attenuation in the postoperative period.
PubMed ID
18004264 View in PubMed
Less detail

Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers.

https://arctichealth.org/en/permalink/ahliterature100437
Source
Int J Tuberc Lung Dis. 2010 Sep;14(9):1209-11
Publication Type
Article
Date
Sep-2010
Author
I. Harstad
B A Winje
E. Heldal
F. Oftung
G W Jacobsen
Author Affiliation
Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway. ingunn.harstad@ntnu.no
Source
Int J Tuberc Lung Dis. 2010 Sep;14(9):1209-11
Date
Sep-2010
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Female
Follow-Up Studies
Humans
Interferon-gamma - immunology
Latent Tuberculosis - diagnosis
Male
Mass Screening - methods
Middle Aged
Norway
Predictive value of tests
Reagent kits, diagnostic
Refugees
Tuberculin Test
Tuberculosis - diagnosis
Young Adult
Abstract
Screening with chest X-ray and the Mantoux test (the tuberculin skin test [TST]) is compulsory for adult asylum seekers who arrive in Norway. In 2005-2006, we included 823 asylum seekers in a study of the QuantiFERON-TB Gold test (QFT-G), and followed them for 23-32 months. Eight subjects with a positive and one with a negative QFT-G test were diagnosed with tuberculosis (TB). The positive (PPV) and negative predictive values (NPV) for TB were respectively 3.3% and 99.8%. The PPV was 2.3% and the NPV 99.1% for TST >or= 15 mm, and the NPV was 99.5% for TST >or= 6 mm in combination with a negative QFT-G.
PubMed ID
20819271 View in PubMed
Less detail

9 records – page 1 of 1.